Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570479 · ClinicalTrials.gov registry record · Phase 1
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
A Phase 1 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00570479 is a Phase 1 study that has completed, run by Texas Retina Associates. The registered enrollment target is 12 participants.
The verdict
NCT00570479, a Phase 1 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA) has been shown to reduce steroid induced elevated IOP. The purpose of this study was to evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to prevent this Retisert induced elevated IOP.
Interventions
- DRUG anecortave acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570479
The ClinicalTrials.gov registry entry for NCT00570479 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Retina Associates, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00570479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570479 about?
NCT00570479 is a clinical study titled "Prophylactic Anecortave Acetate in Patients With a Retisert Implant". Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required i...
What is the current status of trial NCT00570479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00570479?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00570479?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.